blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2601969

EP2601969 - Norovirus vaccine formulations [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.02.2017
Database last updated on 15.06.2024
Most recent event   Tooltip20.07.2018Lapse of the patent in a contracting state
New state(s): MT		published on 22.08.2018  [2018/34]
Applicant(s)For all designated states
Takeda Vaccines, Inc.
One Takeda Parkway
Deerfield, IL 60015 / US
[2015/47]
Former [2013/24]For all designated states
Ligocyte Pharmaceuticals, Inc.
2155 Analysis Drive
Bozeman, MT 59718-6831 / US
Inventor(s)01 / Richardson, Charles
c/o Takeda Vaccines, Inc.
One Takeda Parkway
Deerfield, IL 60015 / US
02 / Vedvick, Thomas S.
c/o Takeda Vaccines, Inc.
One Takeda Parkway
Deerfield, IL 60015 / US
03 / Foubert, Thomas R.
c/o Takeda Vaccines, Inc.
One Takeda Parkway
Deerfield, IL 60015 / US
04 / Tino, William T.
c/o Takeda Vaccines, Inc.
One Takeda Parkway
Deerfield, IL 60015 / US
 [2016/13]
Former [2013/27]01 / Richardson, Charles
c/o Ligocyte Pharmaceuticals, Inc.
2155 Analysis Drive
Bozeman, MT 59718 / US
02 / Vedvick, Thomas S.
c/o Ligocyte Pharmaceuticals, Inc.
2155 Analysis Drive
Bozeman, MT 59718 / US
03 / Foubert, Thomas R.
c/o Ligocyte Pharmaceuticals, Inc.
2155 Analysis Drive
Bozeman, MT 59718 / US
04 / Tino, William T.
c/o Ligocyte Pharmaceuticals, Inc.
2155 Analysis Drive
Bozeman, MT 59718 / US
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2016/13]
Former [2013/24]HOFFMANN EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München / DE
Application number, filing date13157572.228.09.2007
[2013/24]
Priority number, dateUS20060847912P29.09.2006         Original published format: US 847912 P
US20070973392P18.09.2007         Original published format: US 973392 P
[2013/24]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2601969
Date:12.06.2013
Language:EN
[2013/24]
Type: A3 Search report 
No.:EP2601969
Date:21.08.2013
Language:EN
[2013/34]
Type: B1 Patent specification 
No.:EP2601969
Date:30.03.2016
Language:EN
[2016/13]
Search report(s)(Supplementary) European search report - dispatched on:EP23.07.2013
ClassificationIPC:A61K39/42, A61K39/12
[2013/24]
CPC:
A61K39/12 (EP,KR,US); A61K39/125 (EP,US); A61K39/39 (US);
A61K39/42 (KR); A61P1/04 (EP); A61P31/14 (EP);
A61P37/04 (EP); A61P9/14 (EP); C07K16/10 (EP,US);
C12N7/00 (US); A61K2039/5258 (EP,US); A61K2039/54 (US);
A61K2039/543 (EP,US); A61K2039/55572 (EP,US); A61K2039/70 (EP,US);
C12N2770/16023 (US); C12N2770/16034 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/13]
Former [2013/24]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:NOROVIRUS-IMPFSTOFF-FORMULIERUNGEN[2013/34]
English:Norovirus vaccine formulations[2013/24]
French:FORMULATIONS DE VACCIN CONTRE UN NOROVIRUS[2013/34]
Former [2013/24]Norovirus-Impfstoff-Formulierungen
Former [2013/24]Formulations de vaccin contre un norovirus
Examination procedure19.02.2014Examination requested  [2014/14]
15.04.2014Despatch of a communication from the examining division (Time limit: M04)
25.08.2014Reply to a communication from the examining division
14.11.2014Despatch of a communication from the examining division (Time limit: M06)
22.05.2015Reply to a communication from the examining division
26.06.2015Communication of intention to grant the patent
16.10.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
17.11.2015Communication of intention to grant the patent
22.01.2016Fee for grant paid
22.01.2016Fee for publishing/printing paid
22.01.2016Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP07853688.5  / EP2066354
Divisional application(s)EP13173005.3  / EP2641613
Opposition(s)03.01.2017No opposition filed within time limit [2017/10]
Fees paidRenewal fee
04.03.2013Renewal fee patent year 03
04.03.2013Renewal fee patent year 04
04.03.2013Renewal fee patent year 05
04.03.2013Renewal fee patent year 06
12.09.2013Renewal fee patent year 07
12.09.2014Renewal fee patent year 08
11.09.2015Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT30.03.2016
CY30.03.2016
EE30.03.2016
LT30.03.2016
LV30.03.2016
RO30.03.2016
SI30.03.2016
SK30.03.2016
TR30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
LU28.09.2016
MT30.09.2016
[2018/33]
Former [2018/29]AT30.03.2016
CY30.03.2016
EE30.03.2016
LT30.03.2016
LV30.03.2016
RO30.03.2016
SI30.03.2016
SK30.03.2016
TR30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
LU28.09.2016
Former [2017/47]AT30.03.2016
EE30.03.2016
LT30.03.2016
LV30.03.2016
RO30.03.2016
SI30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
LU28.09.2016
Former [2017/37]AT30.03.2016
EE30.03.2016
LT30.03.2016
LV30.03.2016
RO30.03.2016
SI30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2016/51]AT30.03.2016
EE30.03.2016
LT30.03.2016
LV30.03.2016
RO30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2016/50]AT30.03.2016
EE30.03.2016
LT30.03.2016
LV30.03.2016
RO30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
Former [2016/49]EE30.03.2016
LT30.03.2016
LV30.03.2016
GR01.07.2016
IS30.07.2016
Former [2016/48]LT30.03.2016
LV30.03.2016
GR01.07.2016
IS30.07.2016
Former [2016/39]LT30.03.2016
LV30.03.2016
GR01.07.2016
Former [2016/36]LT30.03.2016
GR01.07.2016
Former [2016/35]GR01.07.2016
Documents cited:Search[A]WO9216543  (GENELABS INC [US], et al) [A] 1,4-16 * the whole document * * In particular: p. 5, l. 26-32; p. 8, l. 13-22; p. 26-27, section B; claim 44. *;
 [A]US5861241  (HERRMANN JOHN E [US], et al) [A] 1,4-16 * the whole document * * In particular: col. 4, l. 22-49. *;
 [A]EP1186890  (JP NAT INST INFECTIOUS DISEASE [JP], et al) [A] 1,4-16 * the whole document * * In particular:paragraphs 80-81. *;
 [A]US2005155113  (HAMILTON WILLIAM D [GB], et al) [A] 1,4-16 * the whole document * * In particular: paragraphs 11-18, 81, 135, 152-156, claims 1-50. *;
 [E]EP2360175  (NOVARTIS VACCINES & DIAGNOSTIC [US]) [E] 1,4-16 * the whole document * * In particular: p. 1, l. 1 - p. 18, l. 29; Section F, pp. 86-99; p. 116, l. 1 - p. 118, l. 25. *;
 [A]  - SINGH M ET AL, "A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens", VACCINE, ELSEVIER LTD, GB, vol. 24, no. 10, doi:10.1016/J.VACCINE.2005.09.046, ISSN 0264-410X, (20060306), pages 1680 - 1686, (20060306), XP028010518 [A] 1,4-16 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2005.09.046
ExaminationEP2190471
by applicantEP0689454
 WO9844944
 WO0045841
 US6942865
    - VINJE ET AL., J. CLIN. MICRO., (2003), vol. 41, pages 1423 - 1433
    - LEITE ET AL., ARCH. VIROL., vol. 141, pages 865 - 875
    - GREEN ET AL., Human Caliciviruses, in Fields Virology, LIPPINCOTT WILLIAMS & WILKINS, (2001), vol. 1, pages 841 - 874
    - CENTERS FOR DISEASE CONTROL, MORBIDITY AND MORTALITY WEEKLY REPORT, (2007), vol. 56, no. 33, pages 842 - 846
    - BERGER; KIMMEL, Guide to Molecular Cloning Techniques, Methods in Enzymology, ACADEMIC PRESS, LNC., vol. 152
    - SAMBROOK ET AL., Molecular Cloning--A Laboratory Manual, COLD SPRING HARBOR LABORATORY, (2000), vol. 1-3
    - Current Protocols in Molecular Biology, GREENE PUBLISHING ASSOCIATES, INC. AND JOHN WILEY & SONS, INC.
    - GLASS, RI; JS NOEL; T ANDO; RL FANKHAUSER; G BELLOIT; A MOUNTS; UD PARASHER; JS BRESEE; SS MONROE, "The Epidemiology of Enteric Caliciviruses from Human: A Reassessment Using New Diagnostics", JLNFECT DIS, (2000), vol. 181, no. 2, pages S254 - S261
    - HARDY, ME; NORWALK, "Epidemic Gastroenteritis", CLIN LAB MED, (1999), vol. 19, no. 3, pages 675 - 90
    - JIANG, X; DY GRAHAM; KN WANG; MK ESTES, "Noralk Virus Genome Cloning and Characterization", SCIENCE, (1990), vol. 250, pages 1580 - 1583
    - JIANG, X; M WANT; DY GRAHAM; MK ESTES, "Expression, Self-Assembly, and Antigenicity of the Norwalk Virus Capsid Protein", J VIROL, (1992), vol. 66, pages 6527 - 6532
    - GLASS, P; LJ WHITE; JM BALL; I LEPARC-GOFFART; ME HARDY; MK ESTES, "Norwalk Virus Open Reading Frame 3 Encodes a Minor Structural Protein", J VIROL, (2000), vol. 74, pages 6581 - 6591
    - LINDESMITH, L; C MOE; S MARIONNEAU; N RUVOEN; X JIANG; L LINDBLAD; P STEWART; J LEPENDU; R BARIC, "Human Susceptiblity and Resistance to Norwalk Virus Infection", NAT MED, (2003), vol. 9, pages 548 - 553
    - PARRINO, TA; DS SCHREIBER; JS TRIER; AZ KAPIKIAN; NR BLACKLOW, "Clinical Immunity in Acute Gastroenteritis Caused by Norwalk Agent", N ENGL J MED, (1977), vol. 297, pages 86 - 89
    - WYATT, RG; R DOLIN; NR BLACKLOW; HL DUPONT; RF BUSCHO; TS THORNHILL; AZ KAPIKIAN; RM CHANOCK, "Comparison of Three Agents of Acute Infectious Nonbacterial Gastroenteritis by Cross-challenge in Volunteers", J INFECT DIS, (1974), vol. 129, page 709
    - BALL, JM; DY GRAHAM; AR OPEKUM; MA GILGER; RA GUERRERO; MK ESTES, "Recombinant Norwalk Virus-like Particles Given Orally to Volunteers: Phase I Study", GASTROENTEROLOGY, (1999), vol. 117, pages 40 - 48
    - TACKET, CO; MB SZTEIN; GA LOSONKY; SS WASSERMAN; MK ESTES, "Humoral, Mucosal, and Cellular Immune Responses to Oral Nowalk Virus-like Particles in Volunteers", CLIN IMMUNOL, (2003), vol. 108, page 241
    - GUERRERO, RA; JM BALL; SS KRATER; SE PACHECO; JD CLEMENTS; MK ESTES, "Recombinant Norwalk Virus-like Particles Administered Intranasally to Mice Induce Systemic and Mucosal (Fecal and Vaginal) Immune Responses", J VIROL, (2001), vol. 75, page 9713
    - NICOLLIER-JAMOT; B, A OGIER; L PIROTH; P POTHIER; E KOHLI, "Recombinant Virus-like Particles of a Norovirus (Genogroup II Strain) Administered Intranasally and Orally with Mucosal Adjuvants LT and LT(R192G) in BALB/c Mice Induce Specific Humoral and Cellular Th1/Th2-like Immune Responses", VACCINE, (2004), vol. 22, pages 1079 - 1086
    - PERIWAL, SB; KR KOURIE; N RAMACHANDARAN; SJ BLAKENEY; S DEBRUIN; D ZHU; TJ ZAMB; L SMITH; S UDEM; JH ELDRIDGE, "A Modified Cholera Holotoxin CT-E29H Enhances Systemic and Mucosal Immune Responses to Recombinant Norwalk Virus-like Particle Vaccine", VACCINE, (2003), vol. 2, no. 1, pages 376 - 385
    - ISAKA, M; Y YASUDA; S KOZUKA; T TANIGUCHI; K MATANO; J MAEYAMA; T KOMIYA; K OHKUMA; N GOTO; K TOCHIKUBO, "Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant", VACCINE, (1999), vol. 18, pages 743 - 751
    - KOZLOWSKI, PA; S CU-UVIN; MR NEUTRA; TP FLANIGAN, "Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women", INFECT LMMUN, (1997), vol. 65, pages 1387 - 1394
    - MESTECKY, J; SM MICHALEK; Z MOLDOVEANU; MW RUSSELL, "Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans", BEHRING INST MITT, (1997), pages 33 - 43
    - WU, HY; MW RUSSELL, "Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system", IMMUNOL RES, (1997), vol. 16, pages 187 - 201
    - EVANS, JT; CW CLUFF; DA JOHNSON; MJ LACY; DH PERSING; JR BALDRIDGE, "Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi 529", EXPERT REV VACCINES, (2003), vol. 2, pages 219 - 229
    - BALDRIDGE, JR; Y YORGENSEN; JR WARD; JT ULRICH, "Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration [In Process Citation", VACCINE, (2000), vol. 18, pages 2416 - 2425
    - YANG, QB; M MARTIN; SM MICHALEK; J KATZ, "Mechanisms ofmonophosphoryl lipid A augmentation of host responses to recombinant HagB from Porphyromonas gingivalis", INFECT IMMUN, (2002), vol. 70, pages 3557 - 3565
    - BALDRICK, P; D RICHARDSON; G ELLIOTT; AW WHEELER, "Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant", REGUL TOXICOL PHARMACOL, (2002), vol. 35, pages 398 - 413
    - BALDRIDGE, JR; P MCGOWAN; JT EVANS; C CLUFF; S MOSSMAN; D JOHNSON; D PERSING, "Taking a toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents", EXPERT OPIN BIOL 7HER, (2004), vol. 4, pages 1129 - 1138
    - PERSING, DH; RN COLER; MJ LACY; DA JOHNSON; JR BALDRIDGE; RM HERSHBERG; SG REED, "Taking toll: lipid A mimetics as adjuvants and immunomodulators", TRENDS MICROBIOL, (2002), vol. 10, pages 32 - 37
    - ILLUM, L, "Nasal drug delivery--possibilities, problems and solutions", J CONTROL RELEASE, (2003), vol. 87, pages 187 - 198
    - ILLUM, L; I JABBAL-GILL; M HINCHCLIFFE; AN FISHER; SS DAVIS, "Chitosan as a novel nasal delivery system for vaccines", ADV DRUG DELIV REV, (2001), vol. 51, pages 81 - 96
    - DAVIS, SS, "Delivery of peptide and non-peptide drugs through the respiratory tract", PHARM SCI TECHNOL TODAY, (1999), vol. 2, pages 450 - 456
    - BACON, A; J MAKIN; P J SIZER; I JABBAL-GILL; M HINCHCLIFFE; L ILLUM; S CHATFIELD; M ROBERTS, "Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens", INFECT IMMUN, (2000), vol. 68, pages 5764 - 5770
    - VAN DER LUBBEN, IM; JC VERHOEF; G BORCHARD; HE JUNGINGER, "Chitosan for mucosal vaccination", ADV DRUG DELIV REV, (2001), vol. 52, pages 139 - 144
    - VAN DER LUBBEN, IM; JC VERHOEF; G BORCHARD; HE JUNGINGER, "Chitosan and its derivatives in mucosal drug and vaccine delivery", EUR J PHARM SCI, (2001), vol. 14, pages 201 - 207
    - LIM, S T; B FORBES; GP MARTIN; MB BROWN, "In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate", AAPS PHARM SCI TECH, (2001), vol. 2, page 20
    - JABBAL-GILL, I; AN FISHER; R RAPPUOLI; SS DAVIS; L ILLUM, "Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice", VACCINE, (1998), vol. 16, pages 2039 - 2046
    - MILLS, KH; C COSGROVE; EA MCNEELA; A SEXTON; R GIEMZA; I JABBAL-GILL; A CHURCH; W LIN; L ILLUM; A PODDA, "Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming- boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin", A INFECT IMMUN, (2003), vol. 71, pages 726 - 732
    - MCNEELA, EA.; I JABBAL-GILL; L ILIUM; M PIZZA; R RAPPUOLI; A PODDA; DJ LEWIS; KH MILLS, "Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement ofTh2 responses and toxin-neutralizing antibodies by formulation with chitosan", VACCINE, (2004), vol. 22, pages 909 - 914
    - MIKSZTA, JA.; VJ SULLIVAN; C DEAN; AM WATERSTON; JB ALARCON; JP DEKKER; JM BRITTINGHAM; J HUANG; CR HWANG; M FERRITER, "Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms", J INFECT DIS, (2005), vol. 191, pages 278 - 288
    - HUANG, J; RJ GARMISE; TM CROWDER; K MAR; CR HWANG; AJ HICKEY; JA MIKSZTA; VJ SULLIVAN, "A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats", VACCINE, (2004), vol. 23, pages 794 - 801
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.